Kriya Secures $320M Series D to Advance Gene Therapies for Chronic Diseases
Kriya Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering gene therapies for chronic diseases, has announced the closing of a $320 million Series D financing. The…
Read More...
Read More...
